Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 17/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817207 | 0.85 | HSD17B10 (0.65) | GPR174MAPTGAAHSD17B10KDM4E | |
| SCHEMBL15450412 | 0.82 | GPR174 (0.90) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450417 | 0.81 | GPR174 (0.66) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450411 | 0.80 | GPR174 (0.91) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450535 | 0.79 | GPR174 (0.67) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450493 | 0.78 | GPR174 (0.91) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450492 | 0.78 | GPR174 (0.65) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15450498 | 0.78 | GPR174 (0.74) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15435890 | 0.78 | GPR174 (0.91) | GPR174MAPTMEN1KMT2ATDP1 | |
| SCHEMBL15435894 | 0.78 | GPR174 (0.74) | GPR174MAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877455-B1 | FUSED QUINONIC COMPOUNDS | CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A (ES) | 2016-08-17 | — | — | EP | disclosed |
| EP-2877455-B1 | FUSED QUINONIC COMPOUNDS | CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A (ES) | 2016-08-17 | — | — | EP | disclosed |
| US-20150175585-A1 | FUSED QUINONIC COMPOUNDS | CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.) (ES) | 2015-06-25 | — | — | US | disclosed |
| US-20150175585-A1 | FUSED QUINONIC COMPOUNDS | CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.) (ES) | 2015-06-25 | — | — | US | disclosed |
| EP-2690094-A1 | Fused quinonic compounds | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690094-A1 | Fused quinonic compounds | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175585-A1 | FUSED QUINONIC COMPOUNDS | STAT3, STAT1, JAK2 | GPR174 3060/4885MAPT 3593/4885MEN1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.